<DOC>
	<DOCNO>NCT02504619</DOCNO>
	<brief_summary>CordIn™ cryopreserved stem/progenitor cell-based product purify CD133+ cell compose ex vivo expand allogeneic UCB cell . The overall study objective evaluate safety efficacy CordIn™ .</brief_summary>
	<brief_title>Allogeneic SCT CordIn™ , Patients With Hemoglobinopathies</brief_title>
	<detailed_description>CordIn™ cryopreserved stem/progenitor cell-based product purify CD133+ cell compose ex vivo expand allogeneic UCB cell . The trial end last patient completes last visit . The overall study objective evaluate safety efficacy CordIn™ : single ex-vivo expand cord blood unit transplantation patient hemoglobinopathy ( sickle cell disease thalassemia major ) follow preparative therapy .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<criteria>Patient candidate allogeneic SCT treatment SCD thalassemia Patients must one partially HLAmatched CBUs Adequate Karnofsky Performance score Lansky PlayPerformance scale Sufficient physiological reserve Signed write informed consent Prior allogeneic HSCT Evidence HIV infection HIV positive serology Evidence active Hepatitis B , Hepatitis C EBV determine serology PCR Active uncontrolled infection Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>